Literature DB >> 18958442

[SSRI and SNRI treatment in children and adolescents. Current views of the benefits and risks].

K Holtkamp1, B Herpertz-Dahlmann.   

Abstract

The risk of suicidal thoughts and behaviours in the treatment of depressive children and adolescents with selective serotonin reuptake inhibitors (SSRI) and selective noradrenalin reuptake inhibitors (SNRI) is slightly but significantly elevated. These treatments in underage patients with anxiety or obsessive-compulsive disorders are however not related to a higher risk of suicidality. Effect sizes of SSRI/SNRI treatment in children and adolescents are medium to high in anxiety disorders (0.69), medium in obsessive-compulsive disorders (0.48), and low in depressive disorders (0.25). Nevertheless, the benefit:risk ratio is still positive in all three disorders.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18958442     DOI： 10.1007/s00115-008-2555-6

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


  10 in total

1.  [Therapy with not yet approved drugs or for not yet approved indications].

Authors:  J Wollenhaupt
Journal:  Z Rheumatol       Date:  2001-12       Impact factor: 1.372

Review 2.  Efficacy and safety of antidepressants for children and adolescents.

Authors:  Jon N Jureidini; Christopher J Doecke; Peter R Mansfield; Michelle M Haby; David B Menkes; Anne L Tonkin
Journal:  BMJ       Date:  2004-04-10

3.  A power primer.

Authors:  J Cohen
Journal:  Psychol Bull       Date:  1992-07       Impact factor: 17.737

4.  Do antidepressants cause suicidality in children? A Bayesian meta-analysis.

Authors:  Eloise E Kaizar; Joel B Greenhouse; Howard Seltman; Kelly Kelleher
Journal:  Clin Trials       Date:  2006       Impact factor: 2.486

Review 5.  [Serotonin reuptake inhibitors in children. Warnings on the administration, results analysis, and recommendations].

Authors:  J M Fegert; B Herpertz-Dahlmann
Journal:  Nervenarzt       Date:  2005-11       Impact factor: 1.214

6.  Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.

Authors:  M A Riddle; E A Reeve; J A Yaryura-Tobias; H M Yang; J L Claghorn; G Gaffney; J H Greist; D Holland; B J McConville; T Pigott; J T Walkup
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-02       Impact factor: 8.829

7.  Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder.

Authors:  Daniel A Geller; Joseph Biederman; S Evelyn Stewart; Benjamin Mullin; Andrés Martin; Thomas Spencer; Stephen V Faraone
Journal:  Am J Psychiatry       Date:  2003-11       Impact factor: 18.112

8.  The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.

Authors:  John S March; Susan Silva; Stephen Petrycki; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Steven McNulty; Benedetto Vitiello; Joanne Severe
Journal:  Arch Gen Psychiatry       Date:  2007-10

9.  Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials.

Authors:  Jeffrey A Bridge; Satish Iyengar; Cheryl B Salary; Rémy P Barbe; Boris Birmaher; Harold Alan Pincus; Lulu Ren; David A Brent
Journal:  JAMA       Date:  2007-04-18       Impact factor: 56.272

10.  Suicidality in pediatric patients treated with antidepressant drugs.

Authors:  Tarek A Hammad; Thomas Laughren; Judith Racoosin
Journal:  Arch Gen Psychiatry       Date:  2006-03
  10 in total
  1 in total

1.  Near infrared spectroscopy study of the frontopolar hemodynamic response and depressive mood in children with major depressive disorder: a pilot study.

Authors:  Masahide Usami; Yoshitaka Iwadare; Masaki Kodaira; Kyota Watanabe; Kazuhiko Saito
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.